Seres Therapeutics, a US-based biotechnology company backed by nutritional health product manufacturer Nestlé Health Science, filed for an initial public offering on Nasdaq on Wednesday that could raise up to $100m.

Seres is working on a cure for clostridium difficile, a form of bacterial bowl infection that affects patients with a weakened immune system. In the US alone, the infection proves fatal for some 14,000 people each year.

The company, which previously operated as Seres Health, has raised $133.5m in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?